Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges

TK Goswami, M Singh, M Dhawan, S Mitra… - Human vaccines & …, 2022 - Taylor & Francis
Autoimmune diseases are caused when immune cells act against self-protein. This
biological self–non-self-discrimination phenomenon is controlled by a distinct group of …

A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders

AN Kamali, SM Noorbakhsh, H Hamedifar… - Molecular …, 2019 - Elsevier
Abstract The T helper 17 (Th17) cells contain a dynamic subset of CD4+ T-cells that are able
to develop into other different lineage subsets, including the Th1-like Th17 cells. These cells …

The emerging role of regulatory cell-based therapy in autoimmune disease

F Ghobadinezhad, N Ebrahimi, F Mozaffari… - Frontiers in …, 2022 - frontiersin.org
Autoimmune disease, caused by unwanted immune responses to self-antigens, affects
millions of people each year and poses a great social and economic burden to individuals …

Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier

JH Esensten, YD Muller, JA Bluestone… - Journal of Allergy and …, 2018 - Elsevier
Forkhead box P3–expressing regulatory T (Treg) cells are essential for self-tolerance, with
an emerging role in tissue repair and regeneration. Their ability to traffic to tissue and …

New biomarkers in SLE: from bench to bedside

R Capecchi, I Puxeddu, F Pratesi, P Migliorini - Rheumatology, 2020 - academic.oup.com
Biomarkers may have a diagnostic or monitoring value, or may predict response to therapy
or disease course. The aim of this review is to discuss new serum and urinary biomarkers …

Natural and modified IL-2 for the treatment of cancer and autoimmune diseases

M Mizui - Clinical Immunology, 2019 - Elsevier
Abstract Interleukin-2 (IL-2) is a pleiotropic cytokine required for both effector lymphocyte
proliferation/differentiation and regulatory T cell expansion/survival. Ability to receive IL-2 …

Targeting regulatory T cells to treat patients with systemic lupus erythematosus

M Mizui, GC Tsokos - Frontiers in immunology, 2018 - frontiersin.org
Regulatory T cells (Tregs) are central in integration and maintenance of immune
homeostasis. Since breakdown of self-tolerance is a major culprit in the pathogenesis of …

CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation

N Kulkarni, HT Meitei, SA Sonar, PK Sharma… - Journal of …, 2018 - Elsevier
CCR6 is a G protein-coupled receptor (GPCR) that binds to a specific chemokine, CCL20.
The role of CCR6-CCL20 is very well studied in the migration of immune cells, but the non …

Mechanisms of action of low-dose IL-2 restoration therapies in SLE

A Ballesteros-Tato, A Papillion - Current Opinion in Immunology, 2019 - Elsevier
Highlights•IL-2 shortage is a hallmark of SLE.•rIL-2 supplementation therapies show
promising clinical benefits.•rIL-2 boosts Treg cells in SLE patients.•IL-2 is a negative …

Modulation of the immune system for the treatment of glaucoma

K Bell, NT und Hohenstein-Blaul… - Current …, 2018 - benthamdirect.com
Background: At present intraocular pressure (IOP) lowering therapies are the only approach
to treat glaucoma. Neuroprotective strategies to protect the retinal ganglion cells (RGC) from …